DA-5223 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2025
How each study uses DA-5223 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- DA-5223
- 1
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses DA-5223 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study to Exploratively Evaluate the Safety, Tolerability and Pharmacokinetics of DA-5223 Compared With DA-5223-R in Healthy Adult SubjectsCompletedPhase 1Dong-A ST Co., Ltd.NCT07633691Written as DA-5223-R
- A Study to Evaluate the Food Effect on the Pharmacokinetics of DA-5223 in Healthy Adult SubjectsWithdrawnPhase 1Dong-A ST Co., Ltd.NCT07007520Written as DA-5223(Fasting)
- A Study to Compare and Evaluate the Safety, Tolerability and Pharmacokinetics Between DA-5223 and DA-5223-R in Healthy Adult SubjectsCompletedPhase 1Dong-A ST Co., Ltd.NCT07007533Written as DA-5223-R